Pharmaceutical

CC-95775 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval

CC-95775 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.

Jul 7, 2023 - 20:00
CC-95775 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

ABBV-101 by AbbVie for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood o...

Next Article

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China grants EUA to Covid-19 vaccine against XBB descendent lineages

China grants EUA to Covid-19 vaccine against XBB descen...

Jun 9, 2023

In N.C., Mandy Cohen built bridges to GOP. Can she find consensus as new CDC director?

In N.C., Mandy Cohen built bridges to GOP. Can she find...

Jul 14, 2023

Robert Winn: Without ‘high-touch’ strategies, cancer’s breakthroughs will increase disparities

Robert Winn: Without ‘high-touch’ strategies, cancer’s ...

Sep 6, 2023